 Indicated for intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues

Indication

Adults: The recommended dose  is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection. 

Adult Dose

Pediatric Patients (2-16 years): The recommended dose  is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Child Dose

Chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²), or acute kidney injury prior hypersensitivity reaction

Contraindication

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. 

The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m²) as well as patients with acute kidney injury. 

Screen patients for acute kidney injury and other conditions that may reduce renal function. 

Gadoscan287mg

Injection

Popular Pharmaceuticals Ltd.

Additional Offers